Published by
The Street
The Street
By Business Wire DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Kirsten Gruis, M.D. as Chief Medical Officer. Dr. Gruis is a board-certified neurologist with 20 years of experience in both clinical medicine and drug development in large and small biopharmaceutical companies. “We are delighted to welcome Dr. Gruis to the DiaMedica team as Chief Medical Officer,” said Rick Pauls, CEO of DiaMedica. “Dr. Gruis has deep experience in neuro…